---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-003214"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:03:54.668937+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Phio Q1 net loss $3.6M; cash $9.0M; Phase 1 trial with AgonOx expected Q2 2023

## Summary
- Net loss of $3.6M ($3.15 per share) vs $2.6M ($2.34 per share) in Q1 2022.
- Cash at March 31, 2023: $9.0M, down from $11.8M at Dec 31, 2022; subsequent equity offering raised ~$1.7M net.
- R&D expenses $2.1M (+35% YoY); G&A $1.5M (+39% YoY).
- Expects to commence Phase 1 ACT trial with partner AgonOx by end of Q2 2023.
- Cash expected to fund operations into Q1 2024.

## SEC filing metadata
- accession: 0001683168-23-003214
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316823003214/0001683168-23-003214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316823003214/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-003214
- JSON: https://secwatch.observer/filing/0001683168-23-003214.json
- Plain text: https://secwatch.observer/filing/0001683168-23-003214.txt

## Key facts
- Earnings Releases
  Phio Pharmaceuticals Corp. reported the quarter ended March 31, 2023 results: net income Net loss increased 36% to approximately $3.6 million, EPS $3.15 per share.
  - Period: the quarter ended March 31, 2023
  - Net income: Net loss increased 36% to approximately $3.6 million
  - EPS: $3.15 per share
  - Result: reported results
  source text: Net loss increased 36% to approximately $3.6 million, or $3.15 per share, for the quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316823003214/0001683168-23-003214-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.